Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1714027

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
	tabling member constituency	Christchurch
	tabling member printed	Sir Christopher Chope
	uin	23829
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 08:57:40 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	242 label Biography information for Sir Christopher Chope

1714079

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Gabapentin
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	23890
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.</p><p>The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 09:02:05 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4471 label Biography information for Rachael Maskell

1714081

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Alcoholic Drinks: Children and Young Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking with Cabinet colleagues to help tackle under-age alcohol use.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	23892
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Guidance from England’s Chief Medical Officer for healthcare professionals is clear, an alcohol-free childhood is the healthiest and best option. The Department promotes this through online platforms such as the NHS.UK website, and the Talk to FRANK online resource. Local authorities promote these guidelines as part of their public health duties.</p><p>The Department for Education’s statutory guidance, Relationships education, relationships and sex education and health education, became mandatory in September 2020. Through this, education on drugs, alcohol, and tobacco became compulsory at state-funded primary and secondary schools, teaching children and young people how to manage influences and pressures, and keep themselves healthy and safe.</p><p>To deter individuals selling alcohol to a person aged under 18 years old, the maximum fine for the offence of persistently selling alcohol to children was increased from £10,000 to £20,000, under s 147A(8) of the 2003 Licensing Act.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 01/05/2024 12:20:25 answering member 4117 label Biography information for Andrea Leadsom
	tabling member	4471 label Biography information for Rachael Maskell

1714094

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases: Surgery
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase the availability of heart valve surgery for (a) women and (b) ethnic minorities.
	tabling member constituency	Sheffield, Brightside and Hillsborough
	tabling member printed	Gill Furniss
	uin	23907
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23908 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4571 label Biography information for Gill Furniss

1714095

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Heart Diseases: Women
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase awareness of the symptoms of heart valve disease in women.
	tabling member constituency	Sheffield, Brightside and Hillsborough
	tabling member printed	Gill Furniss
	uin	23908
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>NHS England continues to work with its partners in raising awareness of aortic stenosis, with a particular focus on women. NHS England is also working to increase access to cardiac surgery. The breathlessness pathway, launched in April 2023, encourages general practitioners to examine all patients for the signs of valvular heart disease. Heart valve disease is a focus for cardiac networks, with pathways in in place to improve early detection of valve disease in the community.</p><p>In November 2023, a dedicated Heart Valve Disease (HVD) Expert Advisory Group was convened to provide NHS England’s Cardiac Transformation Programme with leadership, advice, quality assurance, expert review, and endorsement of the projects and deliverables that comprise the HVD workstream, with a focus on improving the speed and equity of access to high quality treatment for heart valve patients.</p><p>To improve the early detection and diagnosis of heart valve disease across England, including aortic stenosis, £2.3 billion has been committed to open 160 community diagnostic centres by March 2025. This will increase the volume of diagnostic activity and further reduce patient waiting times. The centres have delivered over 5 million additional tests since July 2021, including those that detect cardiovascular disease.</p><p>In addition, the National Health Service is investing in cardiac networks to support whole pathway improvements. These networks have been developed to take an evidenced based, clinically led, whole pathway approach to improvement, from prevention, diagnosis, treatment, and through to end-of-life care.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 23907 question first answered 01/05/2024 08:52:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4571 label Biography information for Gill Furniss

1714123

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Shingles: Warrington
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help increase uptake of the shingles vaccine by people aged over 65 in Warrington.
	tabling member constituency	Warrington South
	tabling member printed	Andy Carter
	uin	23963
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The Joint Committee on Vaccination and Immunisation has recommended that those who are eligible for the shingles vaccine should change, to allow individuals to be protected at an earlier age, particularly those that have a weakened immune system. Based on the evidence, they recognised that there may be more clinical benefit from starting shingles vaccinations at a lower age, with modelling indicating that a greater number of cases of shingles would be prevented with vaccination at 60 years old for immunocompetent individuals, and 50 years old for immunosuppressed individuals. The committee advised that the programme should be implemented in stages, starting with those that are over 50 years old with a weakened immune system and those turning 65 and 70 years old, then eventually moving down to those turning 60 years old. This is a similar pattern to the roll out of the shingles vaccine from 2013. This is why the vaccine offer has been expanded to all those turning 65 and 70 years old and all those over 50 years old with a weakened immune system, from 1 September 2023. The programme began on 1 September 2023 and will run until 31 August 2028, offering the vaccine to people as they turn 65 and 70 years old, until the offer has been made to all those aged 65 to 70 years old. It will then expand to offering the vaccine to all those that are turning 60 and 65 years old, from 1 September 2028.</p><p>The shingles vaccine is available through general practice (GP) surgeries in primary care, and GPs are required to identify and put in place a call or recall arrangement to offer the shingles vaccination to eligible patients. All eligible patients are contacted by their GP surgery to invite them for vaccination. The GP will then follow up with letters or with calls and text messages, to encourage eligible people that have not come forward to take up the offer.</p><p> </p><p>There is a wide range of public facing information to help increase uptake of the shingles vaccine, and to publicise the programme in GP surgeries and online, including display bunting, leaflets, and posters. GPs are also adding messages regarding shingles to their practice websites, prescription counterfoils, and social media banners. Public facing information regarding the shingles vaccination programme includes translations into over 20 different languages including braille, audio, large print, and British Sign Language. Information for healthcare professionals, including GP toolkits for improving uptake of shingles vaccination, has also been produced and published by local immunisation commissioning teams.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 01/05/2024 12:52:34 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4791 label Biography information for Andy Carter

1714139

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Professions: Labour Turnover
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with Integrated Care Boards on recruitment and retention of health workers.
	tabling member constituency	Bristol South
	tabling member printed	Karin Smyth
	uin	23888
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>The NHS Long Term Workforce Plan sets out how we will meet the workforce needs of the future, through increasing training numbers and reforming training, working differently, and taking action to retain more staff.</p><p>There are a number of key national programmes aimed at supporting regions, integrated care boards (ICBs), and providers with recruitment challenges, and growing the workforce. For example, the Overhauling Recruitment programme aims to overhaul and modernise National Health Service recruitment, encouraging innovation and wider access into NHS careers, supporting the growth of a diverse and skilled workforce to meet future demands on healthcare. NHS England will soon be engaging with ICBs and providers to support and enable this transformational change, as it prepares to publish the overhauling recruitment strategic delivery framework.</p><p>The NHS Long Term Workforce Plan also sets out how to improve culture and leadership to ensure that up to 130,000 fewer staff leave the NHS over the next 15 years. Key to this is the National Retention Programme. The programme builds on the NHS People Promise, and supports integrated care systems (ICS), which are made up of ICBs and integrated care partnerships, regions, NHS trusts, and organisations, to improve employee experience and retain their people, thereby reducing NHS staff leaver rates.</p><p> </p><p>Support for organisations and ICS can be accessed via the Retention Hub, which outlines initiatives mapped against the People Promise, access to tools, guides, and case studies, to enable improvements and contact details for regional colleagues to support the retention agenda in each of the seven regions.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 11:26:40 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4444 label Biography information for Karin Smyth

1714143

	registered interest
	date	26/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pancreatic Cancer: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she has had with NHS England on progress on improving outcomes for patients suffering from pancreatic cancer.
	tabling member constituency	Chipping Barnet
	tabling member printed	Theresa Villiers
	uin	23840
	answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Tackling cancer is a key priority for the Government. Ministers and officials continue to work closely with NHS England to increase positive outcomes for all cancer types, including pancreatic cancer. The National Health Service is delivering a range of interventions expected to increase early diagnosis and improve outcomes for those with pancreatic cancer. This includes: providing a route into pancreatic cancer surveillance for those at inherited high-risk, to identify lesions before they develop into cancer, and diagnose cancers sooner; creating new pathways to support faster referral routes for people with non-specific symptoms that could be linked to a range of cancer types; and increasing direct access for general practitioners to arrange diagnostic tests.</p><p> </p><p>NHS England is also funding a new audit into pancreatic cancer to increase the consistency of access to treatments, and to stimulate improvements in cancer treatment and outcomes. The Royal College of Surgeons began work on this audit in October 2022, and the first report is expected in October 2024. In addition to this, the Getting it Right First Time team in NHS England is undertaking a deep dive into pancreatic cancer, which will highlight actions NHS providers need to take to improve services, as well as gathering examples of good practice to share.</p><p>The NHS is working towards its Long Term Plan ambition of diagnosing 75% of stageable cancers at stage one and two by 2028. Achieving this will mean that an additional 55,000 people each year will survive their cancer for at least five years after diagnosis. With progress made on reducing waiting times, cancer is being diagnosed at an earlier stage more often, with survival rates improving across almost all types of cancer.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 09:23:30 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	1500 label Biography information for Theresa Villiers

1713829

	registered interest
	date	25/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the cost to NHS England has been of reimbursing GP practices for providing services to (a) non-UK and (b) non-registered UK citizens in each of the last three years for which information is available.
	tabling member constituency	Christchurch
	tabling member printed	Sir Christopher Chope
	uin	23670
	answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>General practices (GPs) are paid for providing essential services to all their patients via global sum payments, which are weighted to take patient needs into account. Therefore, there are no dedicated GP payments for providing services to non-United Kingdom or non-registered UK citizens, and the Department does not hold data on GP patient lists by nationality.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 30/04/2024 21:20:59 answering member 4117 label Biography information for Andrea Leadsom previous answer version 31584 answering member constituency South Northamptonshire answering member printed Andrea Leadsom answering member 4117 label Biography information for Andrea Leadsom
	tabling member	242 label Biography information for Sir Christopher Chope

1713889

	registered interest
	date	25/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	National Learning Disability Board
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when the National Learning Disability Board last met.
	tabling member constituency	Romsey and Southampton North
	tabling member printed	Caroline Nokes
	uin	23729
	answer	answer is ministerial correction date of answer 30/04/2024 answer text <p>The final meeting of the National Learning Disability Board took place on 19 July 2016. More information is available at the following link:</p><p><a href="https://www.gov.uk/government/groups/learning-disability-programme-board#minutes" target="_blank">https://www.gov.uk/government/groups/learning-disability-programme-board#minutes</a></p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 30/04/2024 16:48:01 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4048 label Biography information for Caroline Nokes